Hepatitis B virus surface gene pre‐S2 mutant as a high‐risk serum marker for hepatoma recurrence after curative hepatic resection

Chia‐Jui Yen, Yu‐Lin Ai, Hung‐Wen Tsai, Shih‐Huang Chan, Chia‐Sheng Yen, Kuang‐Hsiung Cheng, Yun‐Ping Lee, Chia‐Wei Kao, Yu‐Chun Wang, Yi‐Lin Chen, Cheng‐Han Lin, Tsunglin Liu, Huey‐Pin Tsai, Jen‐Ren Wang, Ih‐Jen Su, Wenya Huang – 19 January 2018 – Chronic hepatitis B virus (HBV) infection is the major cause of hepatocellular carcinoma (HCC). The pre‐S2 mutant large HBV surface antigen (LHBS) is highly associated with HCC.

Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench‐to‐bedside

Shoichi Kageyama, Kojiro Nakamura, Takehiro Fujii, Bibo Ke, Rebecca A. Sosa, Elaine F. Reed, Nakul Datta, Ali Zarrinpar, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski – 19 January 2018 – Hepatic ischemia‐reperfusion injury (IRI) represents a major risk factor of early graft dysfunction and acute/chronic rejection as well as a key obstacle to expanding the donor pool in orthotopic liver transplantation (OLT).

Incidence and cost analysis of hospital admission and 30‐day readmission among patients with cirrhosis

Sakkarin Chirapongsathorn, Chayakrit Krittanawong, Felicity T. Enders, Richard Pendegraft, Kristin C. Mara, Bijan J. Borah, Sue L. Visscher, Conor G. Loftus, Vijay H. Shah, Jayant A. Talwalkar, Patrick S. Kamath – 18 January 2018 – We examined risks for first hospitalization and the rate, risk factors, costs, and 1‐year outcome of 30‐day readmission among patients admitted for complications of cirrhosis.

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis

Michael Praktiknjo, Jennifer Lehmann, Mette J. Nielsen, Robert Schierwagen, Frank E. Uschner, Carsten Meyer, Daniel Thomas, Christian P. Strassburg, Flemming Bendtsen, Søren Møller, Aleksander Krag, Morten A. Karsdal, Diana J. Leeming, Jonel Trebicka – 18 January 2018 – Patients with end‐stage liver disease develop acute decompensation (AD) episodes, which become more frequent and might develop into acute‐on‐chronic liver failure (ACLF). However, it remains unknown how AD induces acceleration of liver disease.

What are the outcomes of declining a public health service increased risk liver donor for patients on the liver transplant waiting list?

Kristopher P. Croome, David D. Lee, Surakit Pungpapong, Andrew P. Keaveny, C. Burcin Taner – 17 January 2018 – The tragedy of the national opioid epidemic has resulted in a significant increase in the number of opioid‐related deaths and accordingly an increase in the number of potential donors designated Public Health Service (PHS) increased risk. Previous studies have demonstrated reluctance to use these PHS organs, and as a result, higher discard rates for these organs have been observed.

Subscribe to